![Hans Schambye](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hans Schambye
Chief Executive Officer at
Boostpharma ApS
Net worth: 149 330 $ as of 2026-05-30
Profile
Hans Thalsgård Schambye was the founder of Profound Pharma AS (founded in 1999), Galecto Biotech ApS (founded in 2011, served as Chief Executive Officer), Damora Therapeutics, Inc. (founded in 2011, served as President, Chief Executive Officer & Director in 2026), and OncoNOx ApS (founded in 2011, served as Chairman).
Current jobs include Chief Executive Officer & Director at BOOST Pharma ApS since 2026 and Chairman at Dansk Biotek.
Former jobs include Chief Executive Officer at Rose Pharma A from 2005 to 2006, Chief Executive Officer at Recepticon ApS from 2006 to 2009, Chairman at Nanoference ApS, Chairman at IO Biotech ApS, Director-Biology & Pharmacology at Maxygen, Inc. from 1999 to 2003, Director at Forward Pharma A, Project Manager at Novo Nordisk A, Principal at Stanford University, Principal at the University of Copenhagen, and Independent Member-Supervisory Board at Step Pharma SAS. Education includes doctorates from the University of Copenhagen and the University of Southern Denmark.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-21 | 6,002 ( 0.01% ) | 149 330 $ | 2026-05-30 |
Hans Schambye active positions
| Companies | Position | Start |
|---|---|---|
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Operates as an industry association for biotech companies with promoting the biotechnological research | Chairman | - |
Boostpharma ApS
 Boostpharma ApS BiotechnologyHealth Technology Develops a stem cell therapy for treatment of osteogenesis imperfecta | Chief Executive Officer | 2026-02-09 |
Former positions of Hans Schambye
| Companies | Position | End |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Chief Executive Officer | 2026-02-09 |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Manufactures galectin modulators for the treatment of severe diseases which includes fibrosis and cancer | Chief Executive Officer | 2026-01-31 |
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology Develops receptor antagonists for prevention of medical induced organ damage | Chief Executive Officer | 2009-10-31 |
Rose Pharma A/S
 Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome | Chief Executive Officer | 2006-07-31 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Corporate Officer/Principal | 2003-11-30 |
Training of Hans Schambye
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
30
1st degree connections
17
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 17 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rose Pharma A/S
Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome | Health Technology |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology Develops receptor antagonists for prevention of medical induced organ damage | Health Technology |
Forward Pharma A/S
 Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Develops and manufactures proprietary formulations for inflammatory and neurological indications | Health Technology |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Operates as an industry association for biotech companies with promoting the biotechnological research | Commercial Services |
Nanoference ApS
 Nanoference ApS Pharmaceuticals: MajorHealth Technology Manufactures medicine for the treatment of infectious pulmonary diseases | Health Technology |
OncoNOx ApS
 OncoNOx ApS Pharmaceuticals: MajorHealth Technology Provides drugs for the treatment of autoimmune diseases and cancer | Health Technology |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Manufactures galectin modulators for the treatment of severe diseases which includes fibrosis and cancer | Health Technology |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Health Technology |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Develops drugs for immunosuppressive therapies | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Boostpharma ApS
Boostpharma ApS BiotechnologyHealth Technology Develops a stem cell therapy for treatment of osteogenesis imperfecta | Health Technology |
- Stock Market
- Insiders
- Hans Schambye
